Related Experiment Video
Updated: Aug 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers
Mary F Hebert1, David K Blough, Robert W Townsend
1University of Washington, Department of Pharmacy, H-375 Health Sciences Center, Box 357630, Seattle, WA 98195-7630, USA. mhebert@u.washington.edu
Abstract:
Tacrolimus is an approved immunosuppressive agent and a known substrate for CYP3A. Micafungin is an echinocandin antifungal agent and a mild inhibitor of CYP3A metabolism in vitro. The objectives of this study were to evaluate the pharmacokinetics of tacrolimus (5 mg oral) and micafungin (100 mg intravenous) alone and with concomitant administration (n=26). Tacrolimus area under the concentration-time curve was 298+/-135 microg*h/L when tacrolimus was administered alone, 305+/-129 microg*h/L (P=.8; confidence interval 89%, 118%) when tacrolimus was given with single-dose micafungin, and 282+/-138 microg*h/L (P=.4; confidence interval 82%, 107%) when tacrolimus was given with steady-state micafungin. Despite the mild inhibition of CYP3A in vitro by micafungin, there does not appear to be a drug interaction with tacrolimus and micafungin either with single-dose or steady-state micafungin administration.
Related Concept Videos
Pharmacodynamic Models: Overview
Dosage Regimens: Partial Pharmacokinetic Parameters
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
